Abemaciclib 150 mg is a specialized therapy utilized in the treatment of patients diagnosed with hormone receptor-positive (HR+) and HER2-negative breast cancer. Currently, access to this medication in Kosovo is restricted, with availability limited to select private pharmacies. The cost of a single package has been reported to be approximately 750 euros.
Despite its recommendation within international clinical guidelines for managing this type of breast cancer, Abemaciclib is not yet included on the national Essential Medicines List (EML). When questioned about its inclusion status, the Ministry of Health stated that it could not confirm whether the drug has been formally proposed for listing at this time. In response to inquiries from Telegrafi, the Ministry confirmed that efforts are underway to update the Essential Medicines List.
The Ministry stated, “The Ministry of Health is continuously working on updating the Essential Medicines List (EML), with the aim of addressing…” This ongoing work signifies the national effort to integrate necessary and recommended treatments, such as this specific therapy for advanced breast cancer, into the standard formulary. The process of updating the EML is crucial for ensuring that guideline-recommended medications become accessible to the broader patient population within the healthcare system.
Topics: #therapy #breast #cancer
